Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-19 · Built: 2026-10-19 · 中文

← United States · Coverage record

US · SEC FORM 4

OKYO Pharma Ltd

OKYO · Nasdaq · CIK 0001849296 · Healthcare · Biotechnology

INSIDER SIGNAL

69.3 / 100

6 buyers · 7 purchase transaction lines · $136.0K gross purchase

WHY THIS SIGNAL?

Buyer breadthStrong
Purchase sizeLow
RoleModerate
RecencyLow
ConvictionStrong
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+35.0 / 35
Purchase size+8.8 / 25
Role+13.0 / 20
Recency+2.5 / 10
Conviction+10.0 / 10

What is holding the score back?

  • ⚠ Purchase size is modest relative to the model scale
  • ⚠ Role scores low · most senior buyer: CHIEF EXECUTIVE OFFICER (CEO, chair and 10% owners score lowest)
  • ⚠ Purchase activity is becoming less recent
  • ✓ Cluster breadth is broad · 4+ insiders

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Purchase breadth & concentration

QUALIFYING BUYERS6
PURCHASE CONCENTRATION50%Largest buyer: CERRONE GABRIELE M · $67.6K
CLUSTER BUYING · 15D6 insidersPeak activity: 2026-07-20–2026-07-27

Roles in the peak window: CHIEF DEVELOPMENT OFFICER, CHIEF EXECUTIVE OFFICER, CHIEF MEDICAL OFFICER, Chief Scientific Officer, Director, Director,TenPercentOwner. Concentration uses priced qualifying P lines only and does not change the saved score.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
CERRONE GABRIELE MDirector,TenPercentOwner
○○●○●
Patil Rajkumar V.Chief Scientific Officer
○●
Dempsey Robert JohnCHIEF EXECUTIVE OFFICER
○●
BRANCACCIO JOHN PDirector
○●
JACOB GARY SCHIEF DEVELOPMENT OFFICER
○●
Mantelli FlavioCHIEF MEDICAL OFFICER
○●
● Purchase▼ Sale○ Other

—

SIGNAL HISTORY

69.3 / 100

Latest recorded score

→ +0.0 ptsversus the previous recorded snapshot
  1. 69.4
  2. 69.4
  3. 69.4
  4. 69.3
  5. 69.3

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

7Purchases
0Sales
8Other Form 4 lines
15SEC filings · 365 days
BUYING7 qualifying P line(s) · 180 days
SELLING0 sale line(s) · context only
OTHER8 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-0.7%
3M
-8.4%
6M
-6.0%
12M
-36.6%

Volatility & liquidity

Volatility
80.2%
Beta
—
Avg daily value
USD 131,605

Valuation

Market cap
—
P/E
—

Fundamentals

Profit margin
—
ROE
—
Industry
Biotechnology

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
34,643
Previous report
42,141
Avg daily volume
76,316
Days to cover
≤ 1.0

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-07-27Patil Rajkumar V.Purchase (P)COMMON STOCK3,363USD 1.49USD 5,011SEC filing ↗
2026-07-22Dempsey Robert JohnPurchase (P)COMMON STOCK15,000USD 1.54USD 23,100SEC filing ↗
2026-07-21Mantelli FlavioPurchase (P)COMMON STOCK20,000USD 1.40USD 28,000SEC filing ↗
2026-07-21JACOB GARY SPurchase (P)COMMON STOCK3,500USD 1.40USD 4,900SEC filing ↗
2026-07-21CERRONE GABRIELE MPurchase (P)COMMON STOCK22,500USD 1.45USD 32,625SEC filing ↗
2026-07-21BRANCACCIO JOHN PPurchase (P)COMMON STOCK5,000USD 1.48USD 7,400SEC filing ↗
2026-07-20CERRONE GABRIELE MPurchase (P)COMMON STOCK25,000USD 1.40USD 35,000SEC filing ↗
2023-09-15BRANCACCIO JOHN PPurchase (P)Ordinary Shares16,670USD 1.50USD 25,005SEC filing ↗
2022-05-19CERRONE GABRIELE MPurchase (P)Ordinary Shares5,800,000USD 0.08USD 464,000SEC filing ↗
2022-05-19JACOB GARY SPurchase (P)American Depositary Shares12,500USD 4.00USD 50,000SEC filing ↗
2022-05-19CERRONE GABRIELE MPurchase (P)American Depositary Shares37,500USD 4.00USD 150,000SEC filing ↗
2022-05-17CERRONE GABRIELE MPurchase (P)Ordinary Shares1,625,000USD 0.06USD 97,500SEC filing ↗
2022-05-17CERRONE GABRIELE MPurchase (P)American Depositary Shares25,000USD 3.87USD 96,750SEC filing ↗

Form 4 evidence

15 transaction lines in the latest 365-day window; 23 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-07-27Patil Rajkumar V.Purchase (P)COMMON STOCK3,363USD 1.49USD 5,011SEC filing ↗
2026-07-27Patil Rajkumar V.Award / grant (A)COMMON STOCK3,363USD 1.49USD 5,011SEC filing ↗
2026-07-22Dempsey Robert JohnPurchase (P)COMMON STOCK15,000USD 1.54USD 23,100SEC filing ↗
Show recent Form 4 evidence (15 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-07-27Patil Rajkumar V.Purchase (P)COMMON STOCK3,363USD 1.49USD 5,011SEC filing ↗
2026-07-27Patil Rajkumar V.Award / grant (A)COMMON STOCK3,363USD 1.49USD 5,011SEC filing ↗
2026-07-22Dempsey Robert JohnPurchase (P)COMMON STOCK15,000USD 1.54USD 23,100SEC filing ↗
2026-07-22Dempsey Robert JohnAward / grant (A)COMMON STOCK15,000USD 1.54USD 23,100SEC filing ↗
2026-07-21Mantelli FlavioPurchase (P)COMMON STOCK20,000USD 1.40USD 28,000SEC filing ↗
2026-07-21JACOB GARY SPurchase (P)COMMON STOCK3,500USD 1.40USD 4,900SEC filing ↗
2026-07-21CERRONE GABRIELE MPurchase (P)COMMON STOCK22,500USD 1.45USD 32,625SEC filing ↗
2026-07-21BRANCACCIO JOHN PPurchase (P)COMMON STOCK5,000USD 1.48USD 7,400SEC filing ↗
2026-07-21JACOB GARY SAward / grant (A)COMMON STOCK3,500USD 1.40USD 4,900SEC filing ↗
2026-07-21CERRONE GABRIELE MAward / grant (A)COMMON STOCK22,500USD 1.45USD 32,625SEC filing ↗
2026-07-21BRANCACCIO JOHN PAward / grant (A)COMMON STOCK5,000USD 1.48USD 7,400SEC filing ↗
2026-07-21Mantelli FlavioAward / grant (A)COMMON STOCK20,000USD 1.40USD 28,000SEC filing ↗
2026-07-20CERRONE GABRIELE MPurchase (P)COMMON STOCK25,000USD 1.40USD 35,000SEC filing ↗
2026-07-20CERRONE GABRIELE MAward / grant (A)COMMON STOCK25,000USD 1.40USD 35,000SEC filing ↗
2026-06-08CERRONE GABRIELE MAward / grant (A)COMMON STOCK300,000USD 1.72USD 516,000SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-19
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerOKYO
CIK0001849296
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2836 Biological Products, (No Diagnostic Substances)
ExchangeNasdaq

Data coverage

Local Form 4 history23 transaction lines from 2022-05-17 to 2026-07-27
13 P purchase lines · 0 S sale lines · 10 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.